ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

Study Finds No Evidence That Statins Cut Cancer Risk

January 27, 2006

Researchers Find Two Types Of MCL Drug Resistance

August 29, 2014

Zerhouni Announces Changes To NIH Peer Review.

June 6, 2008

Tumor Treating Fields Therapy Increased Three-Year Survival

November 25, 2011

Report Calls For Reinvigorated Cancer Program With Increased Funding, Greater Collaboration.

May 9, 2008

NCI, Six Centers Begin Feasibility Study Of Spiral CT For Lung Cancer Screening.

September 8, 2000